Viking Therapeutics heats up competition in obesity with impressive Phase 2 data
Arctic Aurora portfolio company Viking Therapeutics opened nearly 100% up on positive weight loss data from a Phase 2 study
Obesity is one of the largest societal and healthcare burdens globally. It is estimated to affect more than 650 million people, who are at a higher risk of developing more than 200 health complications including diabetes, cardiovascular problems, and fatty liver disease. In the recent years, multiple drugs have been developed to address this global challenge.
Arctic Aurora LifeScience and Arctic Aurora Biotech Select portfolio company Viking Therapeutics is a strong contender in the obesity space. Today, they announced competitive Phase 2 results of their drug candidate, VK2735. Obese patients in the trial achieved a placebo-adjusted weight loss of up to 13.1% after just 13 weeks. Importantly, weight loss did not plateau at 13 weeks and the treatment was effective in most patients with 88% of them achieving a ≥10% weight loss at the end of the trial. The side effects of the drug were comparable to other similar treatments.
VK2735 is a dual activator of the glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors. Effect on these receptors is associated with reduced body weight and appetite, and higher sensitivity to insulin. Among the drugs that are already approved, semaglutide (brand name Ozempic/Wegovy, marketed by Novo Nordisk) acts on GLP-1 while tirzepatide (Mounjaro/Zepbound by Eli Lilly) is a dual activator of the GLP-1/GIP receptors similarly to VK2735. According to consensus, the size of the obesity market will reach USD 100-150 billion and the peak sales of semaglutide and tirzepatide are expected to be USD 40 billion and USD 45 billion, respectively.
Latest news
Arctic Asset Management - Vera Therapeutics soars on strong Phase 3 results in rare kidney disease
Arctic Aurora LifeScience and Arctic Aurora Biotech Select holding Vera Therapeutics increased more than 65% on June 2, upon announcing competitive phase 3 clinical data in IgAN, a severe kidney disorder.
Arctic Asset Management - Markedskommentar mai 2025
Mai måned viste en sterk utvikling i globale finansmarkeder, preget av økt risikovilje etter turbulensen i april. Verdensindeksen (MSCI World i NOK) steg 5,9 %, mens amerikanske aksjer, representert ved S&P 500 (USD), økte med 6,2 %. Oslo Børs (OSEFX, NOK) hadde også en positiv måned med en oppgang på 5,3 %, drevet av bred sektoroppgang hvor spesielt energi og finans bidro sterkt, mens sektoren defensivt konsum trakk ned, hovedsakelig på grunn av svak utvikling innen lakseoppdrett. Norden (VINX Index, NOK) steg markedet med 2,6 %, hvor industri og finans var de største positive bidragsyterne, mens eiendom bidro negativt.
Arctic Asset Management - The take outs in biotech continues
Sanofi acquires Arctic Aurora LifeScience portfolio company Blueprint Medicines.
On 2 June 2025, the French pharmaceutical company announced its agreement to acquire the Boston-based biotech company Blueprint Medicines in a deal valued at 9.5 billion USD. The acquisition centres on Blueprint's flagship drug, Ayvakit (avapritinib), which is the only approved treatment for advanced systemic mastocytosis in both the EU and the US.
Arctic Asset Management - Gjeld, usikkerhet og en fisk med potensial
I mai-episoden av Arctic Midt i Måneden ser vi nærmere på USAs økende gjeld og spør om landet har økonomisk styrke til å håndtere renteutgiftene. Vi snakker også om hvorfor "usikkerhet" er blitt et nøkkelord i årets rapporteringssesong, hvordan fondene er posisjonert – og hva som gjør en fisk til et fristende investeringscase. Forvalterne Trond Tømmerås og Alexander Larstedt Lager er gjester i studio hos investeringsdirektør Albert Collett.
Arctic Asset Management - What has caused the recent volatility in the healthcare sector?
Arctic Aurora LifeScience's CIO, Ulrica Slåne Bjerke, and portfolio manager, Daniel Bolanowski, share their thoughts on what caused the sector's bumpy ride in April and the first few days of May.
Arctic Asset Management - Markedskommentar april 2025
Nyhetsbildet i april var preget av sterke utspill fra president Trump der hans ‘Liberation Day’ tariff-annonseringer 2. april skapte ekstreme svingninger i finansmarkedene de påfølgende dagene.